Altintas Engin, Kacar Sabite, Tunc Bilge, Sezgin Orhan, Parlak Erkan, Altiparmak Emin, Saritas Ulku, Sahin Burhan
Mersin University, School of Medicine, Division of Gastroenterology, Mersin, Turkey.
J Gastroenterol Hepatol. 2004 Dec;19(12):1388-91. doi: 10.1111/j.1440-1746.2004.03491.x.
Some benign esophageal strictures are highly resistant to bougie dilation. The aim of this study was to determine whether intralesional steroid injection had additional benefit to Savary-Gilliard's bougie dilation therapy (SGBD).
Twenty-one patients were treated with a bougie dilator. The patients were randomized into control and study groups. There were 11 patients in the control group (7 males, 4 females; mean age 45.09 +/- 24.64 years) and 10 patients in the study group (4 males, 6 females; mean age 49.40 +/- 16.49 years). The patients in the control group underwent only SGBD, but patients in the study group received an additional intralesional steroid injection (8 mg triamcinolone acetate into each quadrant). The number of dilations was divided by the follow-up period (in months) to determine the periodic dilatation index.
There was no difference in age, sex, etiology, localization and recurrence of lesions, treatment outcome, complications and the number of dilations between the study and control groups. In the study group, the mean periodic dilatation index was 0.712 (range 0.097-2.75) and 0.289 (range 0-1) before and after injections, respectively (P = 0.03). Additionally, the mean number of dilations was 5.3 (range 2-11) and 1.6 (range 0-5) before and after injections, respectively (P = 0.03). The mean symptom-free interval was 24 +/- 12.75 months in the study group and 5.18 +/- 5.06 months in the control group (P < 0.001). The total periodic dilatation index was 0.193 +/- 0.123 in the study group, while it was 0.597 +/- 0.583 in the control group (P < 0.05).
It can be concluded that intralesional steroid injections increase efficacy of bougie dilation and decrease the requirement for repetition of bougie dilatation.
一些良性食管狭窄对探条扩张术具有高度抗性。本研究的目的是确定病灶内注射类固醇对Savary - Gilliard探条扩张疗法(SGBD)是否具有额外益处。
21例患者接受探条扩张治疗。患者被随机分为对照组和研究组。对照组有11例患者(7例男性,4例女性;平均年龄45.09±24.64岁),研究组有10例患者(4例男性,6例女性;平均年龄49.40±16.49岁)。对照组患者仅接受SGBD,而研究组患者额外接受病灶内类固醇注射(每个象限注射8mg醋酸曲安奈德)。将扩张次数除以随访时间(以月为单位)来确定定期扩张指数。
研究组和对照组在年龄、性别、病因、病变部位和复发情况、治疗结果、并发症以及扩张次数方面均无差异。在研究组中,注射前和注射后的平均定期扩张指数分别为0.712(范围0.097 - 2.75)和0.289(范围0 - 1)(P = 0.03)。此外,注射前和注射后的平均扩张次数分别为5.3(范围2 - 11)和1.6(范围0 - 5)(P = 0.03)。研究组的平均无症状间隔时间为24±12.75个月,对照组为5.18±5.06个月(P < 0.001)。研究组的总定期扩张指数为0.193±0.123,而对照组为0.597±0.583(P < 0.05)。
可以得出结论,病灶内注射类固醇可提高探条扩张的疗效并减少探条扩张重复的需求。